| abstract |
The invention relates to an increase in the expression and / or scretion of sPLA 2 -IAA by the inhibition of certain signaling pathways. The expression of sPLA 2 -IAA (secretory phospholipase A 2 , group IIA) is according to the invention by inhibitors of the Rho / Rho kinase pathway, the Ras / Raf / MEK / ERK signaling pathway and the Ras / PI3 kinase / Akt signaling pathway increased. These inhibitors are therefore suitable according to the invention for the treatment of diseases characterized by defective expression and / or secretion of sPLA 2 -IIA, and for the treatment of bacterial or fungal infectious diseases to sepsis. A combination of different inhibitors leads to a synergistic increase in sPLA 2 -IAA expression or secretion. In addition, lower inhibitor concentrations can be used in the combination than when used alone. |